Sign up to save your podcasts
Or
Share Enhanced Solid Tumor NGS Panel Broadens Genetic-Variants Detection: Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Enhanced Solid Tumor NGS Panel Broadens Genetic-Variants Detection: Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S.
Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' augmented MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted cancer therapy.
(00:31)
Can you tell us a little about yourself and your background — Beth?
(01:24)
Stephanie, what about you?
(01:42)
Dr. Jenkins, a little bit about yourself and your background, please?
(02:25)
Could you provide a brief overview of the new MayoComplete Solid Tumor assay and the enhancements we've provided?
(04:02)
What changes did you incorporate into the test?
(04:57)
Why are copy number variants and loss of heterozygosity important, and how are they used in patient care?
(07:12)
Does including these genes guide patient care in a more valuable way?
(07:51)
What alternative test options are available and how do they compare to the MayoComplete Solid Tumor Panel?
(10:27)
Is having many options available in a one-stop shop important to help guide patient management?
(11:57)
Do you have anything else you'd like to add about the MCSTP enhancements and what the new test assay will deliver in terms of clinical utility or patient care?
View all episodes
By Mayo Clinic Laboratories
5
2121 ratings
Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' augmented MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted cancer therapy.
(00:31)
Can you tell us a little about yourself and your background — Beth?
(01:24)
Stephanie, what about you?
(01:42)
Dr. Jenkins, a little bit about yourself and your background, please?
(02:25)
Could you provide a brief overview of the new MayoComplete Solid Tumor assay and the enhancements we've provided?
(04:02)
What changes did you incorporate into the test?
(04:57)
Why are copy number variants and loss of heterozygosity important, and how are they used in patient care?
(07:12)
Does including these genes guide patient care in a more valuable way?
(07:51)
What alternative test options are available and how do they compare to the MayoComplete Solid Tumor Panel?
(10:27)
Is having many options available in a one-stop shop important to help guide patient management?
(11:57)
Do you have anything else you'd like to add about the MCSTP enhancements and what the new test assay will deliver in terms of clinical utility or patient care?
More shows like Answers from the Lab
View all
Freakonomics Radio
32,258 Listeners
HistoryExtra podcast
3,213 Listeners
20/20
11,953 Listeners
48 Hours
10,955 Listeners
The Daily
113,069 Listeners
Up First from NPR
56,843 Listeners
Dateline NBC
47,516 Listeners